Viking Therapeutics Stock News

Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.

Viking Therapeutics Inc.'s stock rose 1.9% early Wednesday to add to its prior-day gains, as analysts welcomed positive data from the company's early trial of an oral weight-loss treatment — the lat

The 'Fast Money' traders weigh in on Viking Thera stock soaring on its obesity pill data.

The oral formulation of Viking's VK2735 helped patients achieve an average placebo-adjusted weight loss of up to 3.3% of their body mass in 28 days. The company thinks taking higher doses over longer

Viking Therapeutics (NASDAQ: VKTX ) stock is up on Tuesday as the company posts positive results from a short-term study of its weight loss drug. These results come from its Phase 1 study of VK2735.

Viking Therapeutics Inc (NASDAQ: VKTX) is up nearly 20% on Tuesday after reporting encouraging early-stage data for its experimental weight-loss oral drug. Is Viking Therapeutics' oral weight-loss dru

The Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.

Viking Therapeutics said on Tuesday its experimental tablet helped reduce weight in patients in an early-stage trial and was shown to be safe and effective in the study.

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the wa

The Nasdaq Composite index is up sharply over the past year, but it contains at least two growth stocks poised to run even higher. Investment bank analysts who follow Viking Therapeutics think the sto

Viking Therapeutics stock has been soaring this year due to optimism about its weight loss drug candidate. The stock is a risky buy, however, as the company isn't profitable or generating any consiste

Three very different potential scenarios for Viking Therapeutics' future seem possible. Only one of these potential scenarios is negative for Viking's shareholders.

Eli Lilly's weight loss drugs are helping it conquer what may become a $100 billion market. Viking Therapeutics recently announced promising trial data for its weight loss candidate -- which works in

The biotech is getting a lot of attention for one of its pipeline drugs. VK2735 looks like it has a solid chance at becoming a blockbuster obesity treatment.

A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.